Is Divalproex a Cost Effective Alternative in the Acute and Prophylactic Treatment of Bipolar I Disorder?
J Clin Psychiatry 1997;58:495-496 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Letter to the Editor
Sir: A recent pharmacoeconomic study concluded that divalproex
is a less costly treatment than lithium in the acute and
prophylactic treatment of patients with bipolar I disorder.
Such a decision-analytic study must rest on hard data, and
hard data supporting the prophylactic properties of divalproex
are unavailable. The authors did mention that no controlled
study assessed the prophylactic efficacy of divalproex, and, to
our knowledge, no such study has been published since then.